Akt-mediated RALY phosphorylation functions as a molecular switch governing c-Myc stability

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The oncoprotein c-Myc is frequently dysregulated in human cancers.
• The precise mechanisms governing c-Myc regulation are not fully understood.

Purpose of the Study:

• To identify novel regulators of c-Myc stability.
• To elucidate the role of RNA-binding proteins in c-Myc regulation.
• To explore the therapeutic potential of targeting the identified regulatory axis.

Main Methods:

• Investigated the interaction between RALY, USP22, and c-Myc.
• Utilized biochemical assays to study protein stabilization and degradation pathways.
• Employed phosphomimetic mutations and synthetic peptides to probe the regulatory mechanism.
• Assessed the anti-tumor effects of targeting the RALY-USP22-c-Myc complex.

Main Results:

• Identified RALY as a post-translational stabilizer of c-Myc.
• Demonstrated that RALY acts as a scaffold, bridging USP22 to c-Myc to prevent degradation.
• Showed that Akt-mediated phosphorylation of RALY at S106 and T160 is crucial for complex formation and c-Myc stabilization.
• Developed a synthetic peptide (RAMi) that disrupts the complex, destabilizes c-Myc, and exhibits anti-tumor activity.

Conclusions:

• Akt-mediated RALY phosphorylation serves as a molecular switch controlling c-Myc stability.
• The RALY-USP22-c-Myc axis represents a promising therapeutic target for cancers with dysregulated c-Myc.
• Targeting this axis with agents like RAMi holds potential for cancer treatment.